LONDON (Reuters) – Britain is reviewing a class of drugs used in a diabetes medicine and a weight-loss treatment sold by Novo Nordisk after some patients reported suicidal or self-harming thoughts, two weeks after similar action by the European Union. Read full story
Exclusive-UK probing Novo's Ozempic, weight-loss drug Saxenda over suicidal, self-harming thoughts
